Skip to content
Open access

Oxidative balance-related metabolite signature and incident cardiovascular disease and type 2 diabetes within the PREDIMED trial.

Sep 2026 · Metabolism: Clinical and Experimental · Vol 184, pp. 156763 · 0 citations · 67 references
Medicine

TL;DR

Most metabolites showed biologically plausible patterns, correlating with specific pro- and antioxidant exposures and including metabolites previously implicated in oxidative stress-related processes, and inversely associated with CVD and T2D risk at baseline.

Abstract

Aim

Despite growing evidence linking better oxidative balance to improved cardiometabolic health, metabolite signatures reflecting oxidative status remain still poorly characterized. We aimed to identify a plasma metabolite signature of the oxidative balance score (OBS) and to examine its association with incident cardiovascular disease (CVD) and type 2 diabetes (T2D).

Methods

The discovery population included 1732 participants at high cardiovascular risk from the PREDIMED study with available plasma metabolomics using LC-MS and OBS data at baseline. The OBS was calculated at baseline and after 1-year of follow-up based on 12 a priori selected pro- and antioxidant dietary and non-dietary lifestyle factors, with higher scores indicating a more favorable antioxidant balance. A set of metabolites predicting OBS was selected from 388 candidate metabolites using elastic net regression. Multivariable Cox models were used to examine the associations between the OBS metabolite signature and incident CVD and T2D.

Results

A subset of 21 metabolites was consistently selected (amino acids, vitamins, nucleotides, lipid species, xenobiotics, and others). The metabolite signature was inversely associated with incident CVD in the baseline sample (HR per SD 0.70; 95% CI 0.61-0.81), but not in the 1-year sample (HR 0.94; 95% CI 0.81-1.09). In addition, baseline (HR 0.70; 95% CI 0.60-0.80) and 1-year (HR 0.84; 95% CI 0.72-0.97) OBS metabolite signatures were inversely associated with T2D risk.

Conclusions

A plasma metabolite signature reflecting oxidative balance-related exposures was inversely associated with CVD and T2D risk at baseline. The association with T2D was also observed when the signature was applied to 1-year measurements and in an independent external cohort, whereas the association with CVD was not replicated at 1 year. Most metabolites showed biologically plausible patterns, correlating with specific pro- and antioxidant exposures and including metabolites previously implicated in oxidative stress-related processes. CLINICAL TRIAL REGISTRATION This trial was registered at controlled-trials.com as ISRCTN35739639.

Read PDF

Similar papers

Open access Aug 2026

Metabolomic profiling refines cardiovascular risk stratification beyond SCORE2-diabetes in patients with concurrent type 2 diabetes and pulmonary dysfunction

In participants with T2D and LFI, adding a metabolomic signature to SCORE2-Diabetes produced a statistically significant but moderate improvement in risk discrimination, which supports further evaluation in independent cohorts and prospective impact studies.

Mei-Li Li, Yan-Yan Shen, You-Wei Huang et al. · 0 citations
Open access Aug 2026

Metabolomics-Defined Subtypes of Prediabetes and Risk of Cardiovascular-Kidney-Metabolic Outcomes

Whether data-driven clustering based on metabolomic biomarkers could define distinct prediabetes subtypes with differential type 2 diabetes, cardiovascular disease, and chronic kidney disease risk is examined and metabolomics-based subtypes may improve risk stratification and support precision prevention strategies.

Fei Chen, Yang Zhang, Weihao Wang et al. · 0 citations
Open access Sep 2026

Metabolomics highlights cardiovascular risk factor links to sphingolipid and one-carbon metabolism in asymptomatic adults

Serine depletion by increased demands of sphingolipid, and possibly transsulfuration pathway, metabolism is associated with elevations in cytotoxic deoxyceramides and reductions in glycine and methionine availability for one-carbon metabolism, a key marker of residual CVD risk.

Mengjiang Huang, D. Tacad, Tong Shen et al. · 0 citations
Sep 2026

Vitamin D metabolites, genetic variants, and risk of cardiovascular diseases among individuals with newly diagnosed type 2 diabetes: a prospective study.

Evidence regarding individual vitamin D metabolites and cardiovascular diseases (CVD) among individuals with type 2 diabetes (T2D) remains limited. This study aimed to investigate the prospective associations of plasma vitamin D metabolites with incident CVD among individuals with newly diagnosed T2D. This study includ...

Tian-Yu Guo, Shi-Yu Zhao, Zi-Jun Tang et al. · 0 citations
Sep 2026

EAT-Lancet Diet-Associated Serum Metabolites Are Linked to Cardiovascular Disease and Mortality.

BACKGROUND Higher adherence to the EAT-Lancet diet is associated with lower risk of cardiovascular disease (CVD) and all-cause mortality. Metabolomic profiling can identify biomarkers underlying these associations. OBJECTIVE To investigate metabolomic markers of the EAT-Lancet diet and risk of CVD and all-cause morta...

Wan-Jin Guan, Jia-Qi Yang, Jing-Sha Chen et al. · 0 citations
Aug 2026

Plasma metabolomics improves prognostic prediction of chronic kidney disease: evidence from a large-scale population-based prospective cohort study.

BACKGROUND Chronic kidney disease (CKD) is a major global health concern associated with increased mortality and cardiovascular events. Traditional clinical models fail to capture the complex metabolic disturbances in CKD progression. This study aimed to assess the value of circulating Nuclear Magnetic Resonance (NMR)...

Chen Jiang, Chengmiao Qiu, Dengren Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.